Streetbeat News

Products Services

AGFY

Agrify Corporation (NASDAQ:AGFY), a leader in cultivation and extraction solutions for the cannabis industry, has announced a deal with Justice Cannabis Co. to provide a comprehensive hydrocarbon extraction and lab equipment package as Justice Cannabis expands into the New Jersey market. This package includes a variety of extraction and lab equipment, as well as a UL-Compliant C1D1 Explosion Proof Room, designed for safe and easy installation.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:32 am

PRTC

PureTech Health announced that the FDA has granted Orphan Drug Designation to LYT-200 for the treatment of Acute Myeloid Leukemia. This designation could potentially accelerate LYT-200's development and approval process, offering a new treatment option for patients with this condition.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:24 am

BCDA

BioCardia has entered into a long-term partnership with StemCardia to advance the latter's investigational pluripotent stem cell product candidate for treating heart failure. BioCardia will be the exclusive biotherapeutic delivery partner throughout the FDA approval process for an investigational new drug application (IND) and the expected Phase I/II clinical trials.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:14 am

PCRX

Pacira Biosciences announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its gene therapy product, PCRX-201 (Enekinragene Inzadenovec), for the treatment of knee osteoarthritis. This designation could expedite the development and review process for PCRX-201, potentially bringing it to market faster.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:12 am

EYEN

NBY

NovaBay Pharmaceuticals and Eyenovia have announced a partnership to co-promote prescription ophthalmic products to U.S. eyecare professionals. This collaboration aims to leverage the strengths of both companies in the eyecare market.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:08 am

NCNA

NuCana's stock price increased following the announcement that the company has been granted a US Patent for 'Phosphoramidate Derivatives For Use In The Treatment Of Cancer; Especially In The Treatment Where The Patient Shows Resistance.'

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:05 am

IONS

Ionis Pharmaceuticals, Inc. announced positive results from a Phase 2 study of ION224, a treatment for metabolic dysfunction-associated steatohepatitis (MASH), meeting primary and important secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

SLN

Silence Therapeutics plc (Nasdaq: SLN) announced positive 36-week data from the ALPACAR-360 phase 2 study of zerlasiran in subjects with high Lp(a) levels, a key risk factor for cardiovascular disease. Zerlasiran aims to lower Lp(a) production, potentially reducing the risk of atherosclerotic cardiovascular disease events.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:01 am

PEPG

PepGen announced that it has received U.S. FDA Orphan Drug and Rare Pediatric Disease designations for PGN-EDO51, aimed at treating Duchenne Muscular Dystrophy. These designations can provide certain benefits, including tax credits and eligibility for seven years of market exclusivity upon approval.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:01 am

FLOKIUSD

Cryptocurrency analyst Rekt Capital suggests FLOKI could reach new highs if it successfully retests two critical resistance levels at $0.000021 and $0.0000625, transforming them into support levels. This analysis comes amid FLOKI's recent token burns, reducing its circulating supply, and a spike in social dominance. Another analyst, Inmortal, also expressed optimism for FLOKI's potential rise, comparing it to the recent surge in PEPE. Currently, FLOKI is trading up 6.46% at $0.0002771.

Portfolio Pulse from Mehab Qureshi

March 13, 2024 | 11:00 am